Spero Reports Preliminary Findings from Phase 1 Clinical Trial of SPR720 and Announces Plans to Advance Program into Proof-of-Concept Clinical Trial in Patients with NTM Pulmonary Disease


You May Also Like

Asterias Biotherapeutics to Report First Quarter 2018 Results on May 9, 2018

FREMONT, Calif., May 03, 2018 (GLOBE NEWSWIRE) -- Asterias Biotherapeutics, Inc. (NYSE American:AST), a ...

Abeona Therapeutics Appoints Carsten Thiel, Ph.D., as Chief Executive Officer

Company strengthens management team with biopharmaceutical veteran bringing extensive commercial experience in life-threatening rare ...